For laboratory research education only. This article summarizes published scientific literature and company-reported trial results. It is not medical advice. Retatrutide is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) for any use. Nothing here suggests that it is safe or effective for any person or animal, and nothing here is an offer of the substance for human or animal use.
Retatrutide is an investigational peptide developed by Eli Lilly and Company under the code LY3437943. It is designed to activate three hormone receptors at once: the GIP receptor, the GLP-1 receptor, and the glucagon receptor. Researchers therefore call it a “triple agonist” (Coskun et al., 2022, Cell Metab).
Retatrutide has drawn wide attention because of the size of the body-weight changes reported in its clinical trials. In the 80-week Phase 3 TRIUMPH-1 trial, Lilly reported a 28.3% average reduction in body weight on the highest dose, versus 2.2% on placebo (Lilly, May 2026). It is also the subject of active FDA and private enforcement against unapproved sellers.
This guide covers its molecular design, how triple agonism differs from single and dual agonists, what the trials reported, known adverse events, and where it stands legally as of November 2026. For background on the three hormones, see GLP-1, GIP, and Glucagon: How Single, Dual, and Triple Receptor Agonists Differ.
Molecular Identity
Retatrutide is a single synthetic peptide chain, not a mixture of three molecules. In laboratory assays it showed balanced activity at the GLP-1 and glucagon receptors and stronger activity at the GIP receptor (Coskun et al., 2022).
| Property | Value |
|---|---|
| Development code | LY3437943 |
| Developer | Eli Lilly and Company |
| Peptide length | 39 amino acid residues |
| Non-standard residues | Aib (2-aminoisobutyric acid) and α-methyl-leucine; C-terminal amide |
| Lipidation | C20 fatty diacid attached to a lysine side chain through a γ-glutamate and linker spacer |
| Molecular formula | C221H342N46O68 |
| Molecular weight | ≈4731 g/mol (calculated from formula) |
| CAS number | 2381089-83-2 |
| Classification | Investigational; not approved anywhere |
Identifiers, formula, and structural features per Wikipedia (Retatrutide), which compiles the INN and registry data.
The fatty diacid lets the molecule bind reversibly to albumin in blood. This slows clearance and is the reason the molecule was developed for once-weekly administration in trials. The non-standard amino acids resist breakdown by the enzyme DPP-4, which rapidly degrades the natural hormones. The same two design strategies appear in tirzepatide and semaglutide.
How Triple Agonism Works
Retatrutide combines three receptor targets that earlier drugs used one or two at a time. Each receptor has a distinct role in metabolic signaling, as described in our GLP-1, GIP, and glucagon explainer.
| Receptor | Natural hormone | Main roles studied in metabolic research |
|---|---|---|
| GLP-1 receptor | Glucagon-like peptide-1 | Glucose-dependent insulin release, slower gastric emptying, appetite signaling in the brain |
| GIP receptor | Glucose-dependent insulinotropic polypeptide | Glucose-dependent insulin release; effects on fat tissue and appetite pathways |
| Glucagon receptor | Glucagon | Liver glucose output and fat oxidation; increased energy expenditure in preclinical models |
| Compound class | Receptors engaged | Example (status) |
|---|---|---|
| Single agonist | GLP-1 | Semaglutide (FDA approved) |
| Dual agonist | GIP + GLP-1 | Tirzepatide (FDA approved) |
| Triple agonist | GIP + GLP-1 + glucagon | Retatrutide (investigational) |
The rationale for adding glucagon receptor activity is that glucagon signaling may raise energy expenditure and liver fat oxidation, complementing the appetite effects of GLP-1. In Lilly’s preclinical and Phase 1 work, the molecule’s pharmacokinetic profile supported once-weekly dosing, and a single dose was followed by body-weight reduction that persisted for weeks (Coskun et al., 2022). How much each receptor contributes to the effects seen in people has not been separated out in human studies.
Clinical Trial Program
Retatrutide has a large, sponsor-run clinical program. Phase 2 results are peer-reviewed; most Phase 3 results so far are company-reported topline data, with full publications still to come. All trials tested several dose levels against placebo under medical supervision.
| Trial | Population | Participants | Length | Reported result (highest dose vs. placebo) | Source |
|---|---|---|---|---|---|
| Phase 2 (NEJM 2023) | Adults with obesity or overweight, no diabetes | 338 | 48 weeks | −24.2% vs. −2.1% body weight | Jastreboff et al., NEJM |
| TRIUMPH-1 (Phase 3) | Adults with obesity or overweight and a weight-related condition, no diabetes | 2,339 | 80 weeks | −28.3% vs. −2.2% body weight | Lilly, May 2026 |
| TRIUMPH-2 (Phase 3) | Adults with type 2 diabetes and obesity or overweight | 1,152 | 80 weeks | −20.8% vs. −4.0% body weight; A1C −1.5 vs. −0.2 points | Lilly, Jul 2026 |
| TRIUMPH-3 (Phase 3) | Adults with BMI ≥35 and established cardiovascular disease | 1,949 | 80 weeks | −22.6% vs. −3.2% body weight; no statistically clear cardiovascular effect | Lilly, Jul 2026 |
| TRANSCEND-T2D-1 (Phase 3) | Adults with type 2 diabetes on diet and exercise alone | 537 | 40 weeks | A1C reduced up to 2.0 points from 7.9% baseline | Lilly via Drugs.com, Jun 2026 |
TRIUMPH-1 also included sub-studies in knee osteoarthritis pain and obstructive sleep apnea, where Lilly reported reductions in pain scores and apnea events (Drugs.com, June 2026).
Two points matter when reading these numbers. Company press releases are not peer-reviewed, and the TRIUMPH-1 figures use Lilly’s “efficacy estimand,” which models outcomes as if participants stayed on treatment. And every result comes from controlled, medically supervised trials using Lilly-manufactured drug, which says nothing about material from other sources.
Reported Adverse Events and Open Questions
Adverse events in the trials were mostly gastrointestinal and rose with dose. The figures below are TRIUMPH-1, highest dose versus placebo (Lilly, May 2026).
| Event | Retatrutide (highest dose) | Placebo |
|---|---|---|
| Nausea | 42.4% | 14.8% |
| Diarrhea | 32.0% | 13.5% |
| Constipation | 26.1% | 10.9% |
| Vomiting | 25.3% | 4.8% |
| Dysesthesia (abnormal skin sensation) | 12.5% | 0.9% |
| Stopped treatment due to adverse events | 11.3% | 4.9% |
Other findings researchers are watching:
- Heart rate. The Phase 2 trial reported dose-dependent increases in heart rate that peaked around 24 weeks and then declined (Jastreboff et al., 2023).
- Dysesthesia. Lilly describes these skin-sensation events as mostly mild to moderate and says most resolved during treatment. Their cause has not been explained in published data.
- Cardiovascular outcomes. TRIUMPH-3 showed no statistically clear effect on major cardiovascular events in either direction (Lilly, Jul 2026).
- Long-term safety. No trial has yet reported data beyond about two years.
Outside trials. Public Citizen reported at least 14 hospitalizations linked to retatrutide use as of June 2026, involving products sold outside clinical trials, and noted that the purity and strength of such products vary widely (Public Citizen, June 2026).
Regulatory and Legal Status as of November 2026
Retatrutide is not approved by the FDA or any other regulator. It is legally available to people only inside registered clinical trials. Lilly has said it plans to submit retatrutide to the FDA in the first quarter of 2027 (Lilly, Jul 2026).
| Date | Development | Source |
|---|---|---|
| Aug 12, 2026 | Lilly sued six companies, including four sellers that labeled retatrutide “research use only,” alleging the products were marketed for human use; Lilly seeks injunctions and disgorgement of profits | Healio; Frier Levitt |
| Jul 23, 2026 | Lilly reported TRIUMPH-2 and TRIUMPH-3 results and set a Q1 2027 FDA submission target | Lilly |
| Jun 2026 | Public Citizen reported that FDA had sent 14 warning letters to retatrutide sellers since 2024 | Public Citizen |
| May 21, 2026 | Lilly reported TRIUMPH-1, the first Phase 3 obesity readout | Lilly |
| 2023 | Phase 2 obesity trial published in the New England Journal of Medicine | Jastreboff et al. |
No compounding pathway. Because retatrutide is not a component of any FDA-approved drug and is not on the compounding bulks lists, pharmacies cannot lawfully compound it. The shortage-based pathway once used for semaglutide and tirzepatide does not apply (Frier Levitt). Retatrutide is also not among the six peptides in HHS’s October 2026 interim compounding policy (AJMC).
“Research use only” labels. FDA and courts look at a seller’s overall marketing, not only its label. Products labeled “for research use only” have been treated as unapproved drugs when websites included dosing charts, injection guidance, or weight-loss claims (Frier Levitt; Healio).
In sport. As an unapproved substance, retatrutide falls under WADA’s class S0, Non-Approved Substances, which is prohibited at all times (DSHS Köln on WADA S0).
Analytical Identity and Quality Testing
Retatrutide is a large, lipidated peptide, which makes identity testing more demanding than for short peptides. Laboratory characterization of any lot should include:
- Mass spectrometry showing the intact mass consistent with the ≈4731 Da molecule. Peptides of this size appear as several multiply charged ions, so the deconvoluted mass is what should be reported (HPLC vs. LC-MS).
- Reversed-phase HPLC purity, reported as percent peak area. Lipidated peptides can carry closely related impurities, such as variants missing the fatty-acid side chain, that only good separation resolves.
- Lot number, test date, and the testing laboratory, so results can be matched to a specific vial (How to Read a COA).
The only retatrutide characterized in published clinical research is Lilly’s own investigational product. Findings from those trials cannot be assumed to apply to material made by anyone else. Public Citizen’s June 2026 report notes that products sold outside trials vary widely in purity and strength (Public Citizen).
Frequently Asked Questions
What is retatrutide?
An investigational peptide from Eli Lilly (LY3437943) that activates GIP, GLP-1, and glucagon receptors. It is being studied for obesity, type 2 diabetes, and related conditions.
Is retatrutide FDA approved?
No. Lilly has said it plans to submit it to the FDA in the first quarter of 2027. Until a decision is made, it is available only through clinical trials.
How is retatrutide different from tirzepatide and semaglutide?
Semaglutide activates the GLP-1 receptor, and tirzepatide activates GIP and GLP-1 receptors. Retatrutide adds glucagon receptor activity, making it a triple agonist. See GLP-1, GIP, and Glucagon.
What did the Phase 3 trials show?
Lilly reported average body-weight reductions of up to 28.3% at 80 weeks in TRIUMPH-1, compared with 2.2% on placebo. These are company-reported topline results, and full peer-reviewed publications are pending.
What side effects were reported?
Mainly nausea, diarrhea, constipation, and vomiting, which increased with dose. Dysesthesia, an abnormal skin sensation, and heart-rate increases were also reported.
Can retatrutide be compounded?
No. It is not a component of an approved drug and is not on the federal compounding lists, so there is no lawful compounding pathway.
Is retatrutide banned in sport?
Yes. As an unapproved substance it falls under WADA’s S0 class, prohibited at all times.
Related Research Library Articles
- GLP-1, GIP, and Glucagon: How Single, Dual, and Triple Receptor Agonists Differ
- What Are Peptides?
- What Are Research Peptides?
- What Is MOTS-c?
- What Is 5-Amino-MQ?
- HPLC vs. LC-MS: Understanding Peptide Purity and Identity Testing
- Peptide Certificate of Analysis: How to Read a COA
References
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234–1247. PMID 35985340
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972
- Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1). May 21, 2026. Lilly
- Eli Lilly and Company. Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials (TRIUMPH-2, TRIUMPH-3). July 23, 2026. Lilly
- Drugs.com MedNews. Lilly’s retatrutide drove improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea (TRIUMPH-1, TRANSCEND-T2D-1). June 6, 2026. Drugs.com
- ClinicalTrials.gov. TRIUMPH-1. NCT05929066
- Public Citizen. Hospitalizations, enforcement gaps, influencers tied to unapproved retatrutide products. June 16, 2026. Public Citizen
- Healio. Eli Lilly files lawsuits against six companies for allegedly selling retatrutide. August 14, 2026. Healio
- Frier Levitt. Lilly’s retatrutide lawsuits: a new enforcement playbook. 2026. Frier Levitt
- AJMC. 5 things to know about HHS’s interim peptide compounding policy. October 2026. AJMC
- German Sport University Cologne. S0: substances not approved for medical use (WADA Prohibited List). DSHS Köln
- Wikipedia. Retatrutide (identifiers and structure). Wikipedia
Research use only. This article is for laboratory research education. Retatrutide is an investigational drug that is not FDA approved and is available to people only through registered clinical trials. It is not a food, dietary supplement, or cosmetic. Nothing in this article is medical advice, an offer of any substance for human or animal use, or a recommendation to use any substance. This article summarizes published literature and company-reported data as of November 2, 2026.
Leave a Reply